|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003250,
umls-concept:C0007634,
umls-concept:C0021083,
umls-concept:C0026764,
umls-concept:C0086418,
umls-concept:C0205195,
umls-concept:C0221102,
umls-concept:C1144149,
umls-concept:C1413221,
umls-concept:C1704419,
umls-concept:C2349975
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-2-1
|
|
pubmed:abstractText |
In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab. Daratumumab is a novel human CD38 monoclonal antibody which kills CD38+ multiple myeloma cells via antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and apoptosis.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-10037006,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-10961386,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-12731664,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-15015893,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-1504309,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-15087402,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-15090448,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-15571458,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-16085014,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-16136504,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-16222306,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-16357183,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-16494942,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-16616068,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-17076650,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-17606735,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-17906076,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-17975015,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-18286284,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-18452080,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-18452408,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-18621417,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-18760706,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-18784738,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-18805433,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-19001137,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-19007331,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-19038762,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-20133895,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-7529064,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-7718903,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21109694-8903511
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
96
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
284-90
|
|
pubmed:meshHeading |
pubmed-meshheading:21109694-Antibodies, Monoclonal,
pubmed-meshheading:21109694-Antibody-Dependent Cell Cytotoxicity,
pubmed-meshheading:21109694-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21109694-Bone Marrow,
pubmed-meshheading:21109694-Complement System Proteins,
pubmed-meshheading:21109694-Cytotoxicity, Immunologic,
pubmed-meshheading:21109694-Humans,
pubmed-meshheading:21109694-Immunophenotyping,
pubmed-meshheading:21109694-Immunotherapy,
pubmed-meshheading:21109694-Multiple Myeloma,
pubmed-meshheading:21109694-Thalidomide,
pubmed-meshheading:21109694-Tumor Cells, Cultured
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
|
|
pubmed:affiliation |
Dept. of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
